Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma
https://www.nature.com/articles/s41467-020-19452-yHelmsauer, K., Valieva, M.E., Ali, S. et al. Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. Nat Commun 11, 5823 (2020). https://doi.org/10.1038/s41467-020-19452-y
Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma
https://www.nature.com/articles/s41588-019-0547-zKoche RP, Rodriguez-Fos E, Helmsauer K, et al. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. Nat Genet. 2020;52(1):29–34. doi:10.1038/s41588-019-0547-z
Genomic DNA transposition induced by human PGBD5
https://elifesciences.org/articles/10565Henssen, A. G., Henaff, E., Jiang, E., Eisenberg, A., Carson, J. R., Villasante, C. M., Ray, M., Still, E., Burns, M., Gandara, J., Feschotte, C., Mason, C. E., Kentsis, A. “Genomic DNA transposition induced by human PGBD5.” eLife, 2015, Sep 25;4. pii: e10565
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=26631615Henssen, A. G., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., De Preter, K., Florin, A., Heukamp, L., Spruessel, A., Astrahanseff, K., Lindner, S., Sadowski, N., Schramm, A., Astorgues-Xerri, L., Riveiro, M. E., Eggert, A., Cvitkovic, E., Schulte, J. H. “Targeting MYCN-driven transcription by BET-bromodomain inhibition.” Clinical Cancer Research 2016, May 15; -22(10):247081.
Forward genetic screen of human transposase genomic rearrangements
https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-016-2877-xHenssen, A. G., Jiang E., Zhuang J., Pinello L., Socci N.D., Koche R., Gonen M., Villasante C. M., Armstrong S. A., Bauer D. E., Weng Z., Kentsis A. “Forward genetic screen of human transposase genomic rearrangements.” BMC Genomics 2016, Aug 4;17:548.
PGBD5 promotes site-specific oncogenic mutations in human tumors
https://www.nature.com/articles/ng.3866Henssen, A.G., Koche, R. Zhuang J., Jiang E., Reed C., Eisenberg A., Still E., MacArthur I.C., Rodríguez-Fos E., Gonzalez S., Puiggròs M., Blackford A.N., Mason C.E., de Stanchina E., Gönen M., Emde A.K., Shah M., Arora K., Reeves C., Socci N.D., Perlman E., Antonescu C.R., Roberts C.W.M., Steen H., Mullen E., Jackson S.P., Torrents D., Weng Z., Armstrong, S.A. & Kentsis, A., “PGBD5 promotes site-specific oncogenic mutations in human tumors.” Nat. Genet. 2017, Jul;49(7):1005-1014.
Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors
http://stm.sciencemag.org/content/9/414/eaam9078Henssen, A.G., Reed, C., Jiang, E., Dorado Garcia, H., von Stebut, J., MacArthur, I.C., Hundsdoerfer, P., Kim, J.H., de Stanchina, E., Kuwahara, Y., Hosoi, H., Ganem, N.J., Dela Cruz, F., Kung, A.L., Schulte, J.H., Petrini, J.H., Kentsis, A. “Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors”. Sci Transl Med, 2017, Nov 1;9(414).
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma
https://www.sciencedirect.com/science/article/pii/S0304383518307274?via%3DihubHan, Y., Lindner, S., Bei, Y., Garcia, H.D., Timme, N., Althoff, K., Odersky, A., Schramm, A., Lissat, A., Künkele, A., Deubzer, H.E., Eggert, A., Schulte, J.H., Henssen A. G. “Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.” Cancer Lett. 2019 Jan 3. pii: S0304-3835(18)30727-4.
Mutational dynamics between primary and relapse neuroblastomas
https://www.nature.com/articles/ng.3349Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., Stephan, H., Schröder, C., Heukamp, L., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Altmüller, J., Nürnberg, P., Astrahantseff, K., Gloeckner, C., De Preter, K., Plass, C., Lee, S., Lode, H.N., Henrich, K.O., Gartlgruber, M., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M., Eggert, A., Schulte J. H. „Mutational dynamics between primary and relapse neuroblastomas“. Nat. Genet. 2015, Aug;47(8):872-7
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets
https://www.nature.com/articles/s41467-018-06699-9Decaesteker, B., Denecker, G., Van Neste, C., Dolman, E.M., Van Loocke, W., Gartlgruber, M., Nunes, C., De Vloed, F., Depuydt, P., Verboom, K., Rombaut, D., Loontiens, S., De Wyn, J., Kholosy, W.M., Koopmans, B., Essing, A.H.W., Herrmann, C., Dreidax, D., Durinck, K., Deforce, D., van Nieuwerburgh, F., Henssen, A., Versteeg, R., Boeva, V., Schleiermacher, G., van Nes, J., Mestdagh, P., Vanhauwaert, S., Schulte, J.H., Westermann, F., Molenaar, J.J., De Preter, K., Speleman, F. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nat Commun. 2018 Nov 19;9(1):4866.